about
Domperidone and levodopa in Parkinson's diseaseEffect of practice on performance of a skilled motor task in patients with Parkinson's disease.Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.Parkinson's disease: a pharmacological updateBehavioral complications of drug treatment of Parkinson's disease.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.
P2860
Q24544087-3E13E6DF-3704-4140-9ED5-1CAE240E1647Q33590808-733DE7EC-7047-4D5E-ADC9-5F8D5FCD88DAQ35166725-840DEDEC-A318-4C33-AB1A-C60828BA4CF7Q36575715-84A88CC0-3FFC-4BC3-8CD4-CA505E41BB6BQ37771070-DBAEC97C-8213-4B95-AFD0-C966DC5ED913Q38223072-931C1523-C8FF-443B-B50E-E8593E3E161CQ38546598-7B3FCD09-A106-4E5E-8974-3359CB63DA43
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Adverse effects of antiparkinsonian drugs.
@en
type
label
Adverse effects of antiparkinsonian drugs.
@en
prefLabel
Adverse effects of antiparkinsonian drugs.
@en
P1433
P1476
Adverse effects of antiparkinsonian drugs.
@en
P2093
J D Parkes
P304
P356
10.2165/00003495-198121050-00002
P577
1981-05-01T00:00:00Z
P6179
1000270120